Biopharmaceutical company GB Sciences (OTCMKTS:GBLX) Stock Attempts To rebound After The Recent Fall

Shares of GB Sciences (OTCMKTS:GBLX) ended higher in the previous after the recent fall.

Market Reaction

On Monday, GBLX stock jumped 4.37% to $0.0282 with 333k shares, compared to its average volume of 323k shares. The stock has moved within a range of $0.0250 – 0.0320 after opening trade at $0.0270.

Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships

Biopharmaceutical company GB Sciences (OTCMKTS:GBLX) has undertaken a number of steps for expediting the process and is developing important relationships for furthering the clinical development of unique, plant-inspired therapies.

The company recognizes the pace of drug research and development processes as well as the adverse impact on patients.

GB Sciences harnesses the revolutionary drug discovery platform, PhaROS, which predicts unique formulations of therapeutic mixtures.

The drug combines knowledge of plant-based medicines with modern data analytics as well as machine learning, allowing the company to reduce time and money for bringing formulations to market.

Dr. Andrea Small-Howard, President and Chief Science Officer at the company said that its R&D processes are innovative. Howard added that it takes over a decade for a new medicine to move from the initial discovery phase to the marketplace making it difficult for millions of people for symptom relief.

The approach to drug discovery augments research efficiency and reduces the company’s time from ideation to drug selection to less than 1.5 years.

The company has been given three US parents for the lead therapies for inflammation, Parkinson’s disease as well as chronic pain. A key relationship for the firm’s development pipeline is Purisys, the preferred partner for the company Active Pharmaceutical Ingredients requirement.

Key Quote

“Our research and development processes are very innovative because we know that the development of novel drugs through traditional biopharmaceutical pipelines is very slow,” says Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. “It typically takes at least 10 years for a new medicine to go from the initial discovery phase to the marketplace, and during that time, millions are left hoping and waiting for symptom relief.”

Traders Review

GBLX stock is trading below the 20-Day and 50-Day Moving averages of $0.0300 and $0.0322 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0494. The stock is down 22% over the past 3-month.

Admin

Leave a Reply

Your email address will not be published. Required fields are marked *